Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Reaffirms Rejection of Helicos Patent

Premium

The United States Patent and Trademark Office has reaffirmed its rejection of the last of four patents owned by Helicos BioSciences that are subject to an inter partes reexamination.

In early January, the USPTO issued a so-called action closing prosecution for the patent, US Patent No. 7,767,400, in which it maintained its initial non-final rejection of all of its claims.

Last year, the office had already issued ACPs for the other three patents under reexamination, US Patents No. 7,037,687, No. 7,169,560, and No. 7,645,596 (IS 10/25/2012).

Pacific Biosciences had requested the reexamination of all four patents last year. The USPTO granted the request last spring, rejecting their claims in a non-final office action.

PacBio's request followed after Helicos sued PacBio, Life Technologies, and Illumina in 2010, claiming that their respective technologies infringe on the patents. That action is still ongoing.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.